Evidence map›Paper›PMID 36152056›Full record

ReviewRheumatology international2023

Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy.

Misako Higashida-Konishi, Mitsuhiro Akiyama, Tatsuya Shimada, Satoshi Hama, Tatsuhiro Oshige, Keisuke Izumi, Hisaji Oshima, Yutaka Okano

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Ocular Manifestations of Giant Cell Arteritis.Advances in ophthalmology and optometry · 2025
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Misako Higashida-KonishiDivision of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, 152-8902, Japan.ORCID http://orcid.org/0000-0001-8712-3852
Mitsuhiro AkiyamaDivision of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, 152-8902, Japan. hhhirooo@hotmail.com.ORCID http://orcid.org/0000-0001-5075-8977
Tatsuya ShimadaDivision of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, 152-8902, Japan.
Satoshi HamaDivision of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, 152-8902, Japan.
Tatsuhiro OshigeDivision of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, 152-8902, Japan.
Keisuke IzumiDivision of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, 152-8902, Japan.ORCID http://orcid.org/0000-0001-8597-0759
Hisaji OshimaDivision of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, 152-8902, Japan.ORCID http://orcid.org/0000-0002-6808-5907
Yutaka OkanoDivision of Rheumatology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, 152-8902, Japan.ORCID http://orcid.org/0000-0003-1373-8840
Keio University · JPTokyo Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucocorticoid remains the mainstay for treatment of large vessel vasculitis (LVV) including giant cell arteritis (GCA); however, the disease affects the elderly for whom the adverse effects of glucocorticoid are problematic. Recently, some reports have suggested that intravenous tocilizumab (TCZ) monotherapy is effective for this disease. To date, it remains unknown whether subcutaneous TCZ monotherapy is also effective. Here, we present a first case of GCA successfully treated with subcutaneous TCZ monotherapy. A 75-year-old woman presented with shoulder and hip pain. She was diagnosed with polymyalgia rheumatica (PMR) and treated with low-dose prednisolone (15 mg daily); however, she discontinued glucocorticoid therapy at her discretion due to the psychiatric adverse effect (cognitive dysfunction). Seven months later, her shoulder and hip pain relapsed. Furthermore,

Indexed as

Drug-Related Side Effects and Adverse ReactionsGiant Cell ArteritisPolymyalgia RheumaticaAgedAntibodies, Monoclonal, HumanizedArthralgiaFemaleFluorodeoxyglucose F18GlucocorticoidsHumansPainPositron Emission Tomography Computed TomographyAntibodies, Monoclonal, HumanizedFluorodeoxyglucose F18GlucocorticoidstocilizumabGiant cell arteritisLarge vessel vasculitisMonotherapyPolymyalgia rheumaticaTocilizumab

Identifiers

PMID36152056
OpenAlexW4297175284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.